From the Journals

Pulmonary embolism confers higher mortality long term


 

Topline

Long-term mortality rates among individuals who have had a pulmonary embolism are significantly higher than rates in the general population.

Methodology

Researchers investigated long-term outcomes of patients with pulmonary embolism in a single-center registry.

They followed 896 patients for up to 14 years.

Data were from consecutive cases treated between May 2005 and December 2017.

Takeaway

The total follow-up time was 3,908 patient-years (median, 3.1 years).

One-year and five-year mortality rates were 19.7% (95% confidence interval, 17.2%-22.4%) and 37.1% (95% CI, 33.6%-40.5%), respectively, for patients with pulmonary embolism.

The most frequent causes of death were cancer (28.5%), pulmonary embolism (19.4%), infections (13.9%), and cardiovascular events (11.6%).

Late mortality (>30 days) was more frequent than in the general population for patients with cancer (5-year standardized mortality ratio, 2.77; 95% CI, 2.41-3.16) and for patients without cancer (1.80; 95% CI, 1.50-2.14), compared with expected rates.

In practice

“The mortality risk of pulmonary embolism patients remained elevated compared to the general population throughout the follow-up period,” stated Johannes Eckelt, Clinic of Cardiology and Pneumology, University Medical Center Göttingen (Germany).

Source

“Long-term Mortality in Pulmonary Embolism: Results in a Single-Center Registry,” by Mr. Eckelt and colleagues was published in Research and Practice in Thrombosis and Haemostasis.

Limitations

Owing to the single-center study design, selection bias cannot be excluded, limiting the generalizability of the study findings, the authors stated.

Disclosures

The authors have disclosed no relevant financial relationships.

A version of this article originally appeared on Medscape.com.

Recommended Reading

VTE prophylaxis overused in low-risk hospitalized patients
MDedge Internal Medicine
Must-read acute care medicine articles from 2022
MDedge Internal Medicine
UnitedHealthcare tried to deny coverage to a chronically ill patient. He fought back, exposing the insurer’s inner workings.
MDedge Internal Medicine
Novel celery seed–derived drug may improve stroke outcomes
MDedge Internal Medicine
Pulmonary embolism workup needed for any sudden onset of exertional dyspnea
MDedge Internal Medicine
Factors linked with increased VTE risk in COVID outpatients
MDedge Internal Medicine
Dabigatran recalled over potential carcinogen
MDedge Internal Medicine
Circulatory support for RV failure caused by pulmonary embolism
MDedge Internal Medicine
Rehabilitation improves walk test results for post–pulmonary embolism patients with persistent dyspnea
MDedge Internal Medicine
Indefinite anticoagulation likely not cost effective after unprovoked VTE
MDedge Internal Medicine